Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line.

Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line.

BACKGROUND/AIM: The mode of action of the somatostatin analog octreotide on neuro-endocrine tumour proliferation is largely unknown. Overexpression of the proto-oncogene Akt/PKB (protein kinase B) has been demonstrated in certain neuro-endocrine tumours: Akt activates downstream proteins including...

書誌詳細
主要な著者:	Grozinsky-Glasberg, S, Franchi, G, Teng, M, Leontiou, C, Ribeiro de Oliveira, A, Dalino, P, Salahuddin, N, Korbonits, M, Grossman, AB
フォーマット:	Journal article
言語:	English
出版事項:	2008

類似資料

Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001).
著者:: Druce, MR, 等
出版事項: (2009)

The Rapamycin Derivative RAD001 (Everolimus) Inhibits Cell Proliferation and Interacts with the Akt-mTOR-p70S6K Pathway in Human Medullary Thyroid Carcinoma Cells
著者:: Grozinsky-Glasberg, S, 等
出版事項: (2009)

The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.
著者:: Grozinsky-Glasberg, S, 等
出版事項: (2010)

Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors
著者:: Yim K-L
出版事項: (2012-07-01)

Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma.
著者:: Michael K Kiessling, 等
出版事項: (2016-01-01)

Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
著者:: Keiko Shoji, 等
出版事項: (2012-01-01)

Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors.
著者:: Dworakowska, D, 等
出版事項: (2009)

RAD001 enhances the potency of BEZ235 to inhibit mTOR signaling and tumor growth.
著者:: Beat Nyfeler, 等
出版事項: (2012-01-01)

The Global mTOR Inhibitor Torin1 Is More Effective than the mTORC1 Inhibitor, Everolimus, Alone or in Combination with Histone Deacetylase Inhibitors, in Suppressing Neuroendocrine Tumor Cell Proliferation
著者:: Grozinsky-Glasberg, S, 等
出版事項: (2011)

Experience with the mTOR Inhibitor Everolimus in Pediatric Liver Graft Recipients
著者:: Mathis Wehming, 等
出版事項: (2023-02-01)

Correction: Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma.
著者:: Michael K Kiessling, 等
出版事項: (2017-01-01)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
著者:: Zhilin Zou, 等
出版事項: (2020-03-01)

Effects of Resveratrol, Lovastatin and the mTOR-Inhibitor RAD-001 on Insulin-Induced Genomic Damage In Vitro
著者:: Eman Awad, 等
出版事項: (2017-12-01)

Escaping mTOR inhibition for cancer therapy: Tumor suppressor functions of mTOR
著者:: Victor H. Villar, 等
出版事項: (2017-05-01)

Repurposing Verapamil to Enhance Killing of T-ALL Cells by the mTOR Inhibitor Everolimus
著者:: Micol Silic-Benussi, 等
出版事項: (2023-03-01)

mTOR, autophagy and reprogramming
著者:: Bor Luen eTang
出版事項: (2014-01-01)

Plasticity and mTOR: Towards Restoration of Impaired Synaptic Plasticity in mTOR-Related Neurogenetic Disorders
著者:: Tanjala T. Gipson, 等
出版事項: (2012-01-01)

AAA + ATPase Thorase inhibits mTOR signaling through the disassembly of the mTOR complex 1
著者:: George K. E. Umanah, 等
出版事項: (2022-08-01)

Synergistic antiproliferative effects of an mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity
著者:: Gigin Lin, 等
出版事項: (2018-08-01)

mTOR Signalling, Nutrients and Disease
著者:: Goberdhan, D, 等
出版事項: (2008)

The mTOR pathway in the antiphospholipid syndrome
著者:: Ji Lanlan, 等
出版事項: (2023-12-01)

mTOR Signaling in Metabolism and Cancer
著者:: Shile Huang
出版事項: (2020-10-01)

The Translational Regulation in mTOR Pathway
著者:: Miaomiao Yang, 等
出版事項: (2022-06-01)

Overview of Research into mTOR Inhibitors
著者:: Beibei Mao, 等
出版事項: (2022-08-01)

Targeting ganglioneuromas with mTOR inhibitors
著者:: Ting Tao, 等
出版事項: (2021-01-01)

Targeting mTOR for cancer therapy
著者:: Hui Hua, 等
出版事項: (2019-07-01)

Successful treatment with the mTOR inhibitor everolimus in a patient with Perivascular epithelioid cell tumor
著者:: Gennatas Constantine, 等
出版事項: (2012-09-01)

Activated mTOR signaling pathway in myofibers with inherited metabolic defect might be an evidence for mTOR inhibition therapies
著者:: Jing-Wei Lyu, 等
出版事項: (2019-04-01)

Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models
著者:: Chun-Ting Kuo, 等
出版事項: (2019-07-01)

mTOR inhibition by everolimus in childhood acute lymphoblastic leukemia induces caspase-independent cell death.
著者:: Rana Baraz, 等
出版事項: (2014-01-01)

Investigation of the effects of mTOR inhibitors rapamycin and everolimus in combination with carboplatin on canine malignant melanoma cells
著者:: Sarah Bernard, 等
出版事項: (2021-12-01)

mTOR Signaling in Growth Control and Disease
著者:: Laplante, Mathieu, 等
出版事項: (2014)

An emerging role of mTOR in lipid biosynthesis
著者:: Laplante, Mathieu, 等
出版事項: (2012)

mTOR Signaling in Growth, Metabolism, and Disease
著者:: Saxton, Robert Andrew, 等
出版事項: (2018)

The mTOR pathway and integrating immune regulation.
著者:: Cobbold, S
出版事項: (2013)

The effects of mTOR inhibition in ischemic stroke
著者:: Schneider, AM
出版事項: (2022)

mTOR Dysregulation, Insulin Resistance, and Hypertension
著者:: Silviu Marcel Stanciu, 等
出版事項: (2024-08-01)

mTOR Inhibition and Tuberous Sclerosis Prevention
著者:: J Gordon Millichap
出版事項: (2013-09-01)

Advances in the regulatory mechanisms of mTOR in necroptosis
著者:: Yawen Xie, 等
出版事項: (2023-12-01)

Roles of mTOR in Diabetic Kidney Disease
著者:: Mako Yasuda-Yamahara, 等
出版事項: (2021-02-01)